Want to see GB:GDR full AI Analyst Report?
GDR Stock Chart & Stats
0.88 p
0.03 p(1.30%)
At close: 4:00 PM EST
0.88 p
0.03 p(1.30%)
Day’s Range― - ―
52-Week Range0.19 p - 1.50 p
Previous CloseN/A
Volume280.42K
Average Volume (3M)49.58M
Market Cap
£20.87M
Enterprise Value7.30M
Total Cash (Recent Filing)£387.00K
Total Debt (Recent Filing)£500.00K
Price to Earnings (P/E)―
Beta-0.64
Next Earnings
Nov 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,605,568,200
10 Day Avg. Volume14,118,826
30 Day Avg. Volume49,583,488
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.48
Price to Sales (P/S)10.31
P/FCF Ratio-1.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Consumables Revenue ModelGenedrive's business mixes capital equipment placement with recurring consumable sales. An installed base that uses single‑use cartridges creates predictable, repeatable revenue and higher lifetime customer value, supporting durable revenue visibility and margin leverage as volumes scale.
Low Leverage / Negligible DebtThe company carries negligible financial debt, which reduces interest and refinancing risk and preserves financial flexibility. This low leverage gives management time to execute commercial plans and raise funding on better terms without imminent debt obligations constraining operations.
Accelerating Revenue GrowthTop-line acceleration indicates improving commercial traction for the Genedrive platform and assays. Sustained revenue growth off a small base can underpin margin expansion and scale benefits over the medium term if the company continues converting instrument placements into recurring consumable sales.
Bears Say
Persistent Cash Burn / Negative FCFMaterial negative operating and free cash flow show the business is not yet self‑funding and relies on external financing. Continued cash burn increases dilution and funding risk, constrains R&D and commercialization investment, and could force adverse financing terms if sustained.
Deep And Recurring LossesSignificant negative EBIT and net losses reflect a cost base well ahead of current scale. Historical margin volatility, including prior periods of weak or negative gross profit, suggests profitability is uncertain and margin recovery will require sustained revenue scale or structural cost reductions.
Compressed Equity Base Limits CushionA sharply reduced equity base leaves little balance‑sheet buffer against further losses and increases the likelihood of future dilution to raise capital. Limited equity weakens resilience to setbacks, narrows strategic options, and elevates governance and funding risk over the medium term.
Genedrive News
GDR FAQ
What was Genedrive PLC’s price range in the past 12 months?
Genedrive PLC lowest share price was 0.19 p and its highest was 1.50 p in the past 12 months.
What is Genedrive PLC’s market cap?
Genedrive PLC’s market cap is £20.87M.
When is Genedrive PLC’s upcoming earnings report date?
Genedrive PLC’s upcoming earnings report date is Nov 24, 2026 which is in 145 days.
How were Genedrive PLC’s earnings last quarter?
Genedrive PLC released its earnings results on Mar 30, 2026. The company reported -0.003 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.003 p.
Is Genedrive PLC overvalued?
According to Wall Street analysts Genedrive PLC’s price is currently Overvalued.
Does Genedrive PLC pay dividends?
Genedrive PLC does not currently pay dividends.
What is Genedrive PLC’s EPS estimate?
Genedrive PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genedrive PLC have?
Genedrive PLC has 1,605,568,200 shares outstanding.
What happened to Genedrive PLC’s price movement after its last earnings report?
Genedrive PLC reported an EPS of -0.003 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.564%.
Which hedge fund is a major shareholder of Genedrive PLC?
Currently, no hedge funds are holding shares in GB:GDR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genedrive PLC
Genedrive Plc, a molecular diagnostics firm established in Manchester, UK, in 2000 (and known as Epistem Holdings Plc until its name change in July 2016), focuses on developing and commercializing innovative point-of-care diagnostic platforms. These solutions cater to a range of applications, including the identification of infectious diseases, genetic profiling, and pathogen detection. At the core of their offerings is the proprietary Genedrive system, a compact polymerase chain reaction (PCR) technology. This advanced platform enables the rapid amplification and detection of nucleic acids from diverse biological samples, such as plasma, sputum, and buccal swabs. The Genedrive platform features several key diagnostic products: the Genedrive HCV ID Kit for qualitative Hepatitis C virus detection; the Genedrive BioPlex, designed for the quick identification of military biothreats from pathogens; and the Genedrive MT-RNR1-ID Kit, a rapid genetic test vital for emergency neonatal care. Complementing these is the Genedrive Connect app, an Android-based mobile application that streamlines data management and facilitates results transmission. Genedrive Plc serves the biotechnology and pharmaceutical sectors globally, with its reach extending throughout the United Kingdom, Europe, the United States, and other international regions. The company has also partnered with Beckman Coulter Life Sciences to automate laboratory PCR testing procedures for COVID-19.
Technical Analysis
EKF Diagnostics Holdings
―
Renalytix
―
Abingdon Health PLC
―
Aptamer Group Plc
―
Oxford Nanopore Technologies PLC
―
Options Prices
Currently, No data available
---